Oregon Partnership for Alzheimer's Research Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2007
NCT00596024
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Oregon Partnership for Alzheimer's Research

Active Ingredients

Drugs in Phase 2 Trials (2)

lutein (1 trial)

zeaxanthin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2